2999 T3D2957 Balsalazide Balsalazide is an anti-inflammatory drug used in the treatment of Inflammatory Bowel Disease. It is sold under the name "Colazal" in the US and "Colazide" in the UK. The chemical name is (E)-5-[[-4-(2-carboxyethyl) aminocarbonyl] phenyl]azo] -2-hydroxybenzoic acid. It is usually administered as the disodium salt. Balsalazide releases mesalazine, also known as 5-aminosalicylic acid, or 5-ASA, in the large intestine. Its advantage over that drug in the treatment of Ulcerative colitis is believed to be the delivery of the active agent past the small intestine to the large intestine, the active site of ulcerative colitis. 80573-04-2 6335412 C17H15N3O6 357.096090 White powder. Freely soluble as disodium salt Oral. Low and variable, intact balsalazide is poorly absorbed systemically. The mechanism of action of 5-aminosalicylic acid is unknown, but appears exert its anti-inflammatory effects locally (in the GI tract) rather than systemically. Mucosal production of arachidonic acid metabolites, both through the cyclooxygenase pathways (catalyzes the formation of prostaglandin precursors from arachidonic acid), and through the lipoxygenase pathways (catalyzes the formation of leukotrienes and hydroxyeicosatetraenoic acids from arachidonic acid and its metabolites), is increased in patients with chronic inflammatory bowel disease. Therefore, it is possible that 5-aminosalicylic acid diminishes inflammation by blocking production of arachidonic acid metabolites in the colon through both the inhibition of cyclooxygenase and lipoxygenase. Cleaved in the colon via bacterial azoreduction to 5-aminosalicylic acid (5&ndash;ASA) and 4-aminobenzoyl-beta-alanine, the inactive carrier moiety. Route of Elimination: The products of the azoreduction of this compound, 5-ASA and 4-aminobenzoyl-beta-alanine, and their N-acetylated metabolites have been identified in plasma, urine and feces. Following single-dose administration of 2.25 g COLAZAL (three 750 mg capsules) under fasting conditions in healthy subjects, mean urinary recovery of balsalazide, 5-ASA, and N-Ac-5-ASA was 0.20%, 0.22% and 10.2%, respectively. Half Life: Half-life could not be determined. No indication of carcinogenicity to humans (not listed by IARC). Used in the treatment of inflammatory bowel disease. [Wikipedia] Symptoms include headache, abdominal pain, upset stomach, dry mouth, yellowing of the skin or eyes, bloating or swelling of the stomach, and fever, sore throat, or flu-like symptoms. (L1870) If an overdose occurs with Balsalazide, treatment should be supportive, with particular attention to correction of electrolyte abnormalities. (L1712) 2009-07-21T20:28:10Z 2026-05-14T16:55:52Z Balsalazide 267413 Balsalazide DB01014 true OC(=O)CCNC(=O)C1=CC=C(C=C1)\N=N\C1=CC=C(O)C(=C1)C(O)=O C17H15N3O6 InChI=1S/C17H15N3O6/c21-14-6-5-12(9-13(14)17(25)26)20-19-11-3-1-10(2-4-11)16(24)18-8-7-15(22)23/h1-6,9,21H,7-8H2,(H,18,24)(H,22,23)(H,25,26)/b20-19+ IPOKCKJONYRRHP-FMQUCBEESA-N 357.3175 357.096085227 Exogenous Solid 1.3 HMDB15149 CHEMBL102265 10662422 <p>Eckardt C. G. Wolf, Nageib Mohamed, Bhaskar Reddy Guntoori, &#8220;Safe process for the preparation of balsalazide.&#8221; U.S. Patent US07271253, issued September 18, 2007.</p> CHEM002320 DTXSID7040653 NS00038077 5-[(1E)-2-{4-[(2-carboxyethyl)carbamoyl]phenyl}diazen-1-yl]-2-hydroxybenzoic acid 148.65 94.37320000000001 35.98486676626132 7 8 4 3.0649272543262662 -0.03339614995957785 -2 2 3.37 -3.76 6.21e-02 g/l